# A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

> **NCT04880850** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 582 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin icodec
- **DRUG:** Insulin glargine
- **DRUG:** Insulin aspart

## Key facts

- **NCT ID:** NCT04880850
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880850, "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04880850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*